MX2023003746A - Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). - Google Patents
Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).Info
- Publication number
- MX2023003746A MX2023003746A MX2023003746A MX2023003746A MX2023003746A MX 2023003746 A MX2023003746 A MX 2023003746A MX 2023003746 A MX2023003746 A MX 2023003746A MX 2023003746 A MX2023003746 A MX 2023003746A MX 2023003746 A MX2023003746 A MX 2023003746A
- Authority
- MX
- Mexico
- Prior art keywords
- rsv
- mva
- respiratory syncytial
- virus
- modified vaccinia
- Prior art date
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 4
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 abstract 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 abstract 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan en la presente cepas de virus vaccinia Ankara modificado (MVA) recombinan te como vacunas mejoradas contra la infección por el virus sincicial respiratorio (virus VSR) y a productos, métodos y usos relacionados. Específicamente, se proporcionan en la presente vectores de MVA recombinan te modificados genéticamente que comprenden al menos una secuencia de nucleótidos que codifica un determinante antigénico de una glicoproteína de membrana de VSR y al menos una secuencia de nucleótidos que codifica un determinante antigénico de una proteína de la nucleocápside de VSR. También se proporcionan en la presente productos, métodos y usos de éste, por ejemplo, apropiados para provocar una respuesta inmunológica en un sujeto o apropiados para diagnosticar una infección de VSR, así como también para determinar si un sujeto está en riesgo de una infección por VSR recurrente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678367P | 2012-08-01 | 2012-08-01 | |
EP12005594 | 2012-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003746A true MX2023003746A (es) | 2023-04-24 |
Family
ID=46614287
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001479A MX362511B (es) | 2012-08-01 | 2013-03-15 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
MX2023003746A MX2023003746A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
MX2019000933A MX2019000933A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001479A MX362511B (es) | 2012-08-01 | 2013-03-15 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000933A MX2019000933A (es) | 2012-08-01 | 2015-01-30 | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). |
Country Status (19)
Country | Link |
---|---|
US (6) | US9480738B2 (es) |
EP (2) | EP2879702B9 (es) |
JP (2) | JP6523955B2 (es) |
KR (3) | KR102264852B1 (es) |
CN (2) | CN109266622B (es) |
AU (1) | AU2013298915B2 (es) |
BR (1) | BR112015002131B1 (es) |
CA (2) | CA2879915C (es) |
CY (1) | CY1122717T1 (es) |
EA (2) | EA031453B1 (es) |
HK (1) | HK1205459A1 (es) |
IL (1) | IL236744B (es) |
IN (1) | IN2015DN01448A (es) |
MX (3) | MX362511B (es) |
MY (1) | MY171498A (es) |
NZ (1) | NZ704005A (es) |
SG (1) | SG11201500696VA (es) |
SI (1) | SI2879702T1 (es) |
WO (1) | WO2014019718A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2879702T (pt) * | 2012-08-01 | 2020-02-04 | Bavarian Nordic As | Vacina para o vírus sincicial respiratório (rsv) de vírus vaccinia modificado recombinante ankara (mva) |
BR112015021781A2 (pt) * | 2013-03-15 | 2017-07-18 | Bavarian Nordic As | alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes |
CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
US11254711B2 (en) | 2015-06-12 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
MX2019011869A (es) | 2017-04-04 | 2020-01-09 | Univ Washington | Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. |
JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
AU2018270375A1 (en) | 2017-05-15 | 2019-10-31 | Bavarian Nordic A/S | Stable virus-containing composition |
CN111801342A (zh) | 2017-12-20 | 2020-10-20 | 葛兰素史密丝克莱恩生物有限公司 | 爱泼斯坦-巴尔病毒抗原构建体 |
US11771755B2 (en) | 2018-02-28 | 2023-10-03 | University Of Washington | Self-asssembling nanostructure vaccines |
EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
WO2020212576A1 (en) * | 2019-04-18 | 2020-10-22 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biological and synthetic molecules inhibiting respiratory syncytial virus infection |
CA3148026A1 (en) * | 2019-08-13 | 2021-02-18 | Vyjayanthi Krishnan | Therapeutic agent effectiveness and its route of administration |
IL296250A (en) | 2020-03-12 | 2022-11-01 | Bavarian Nordic As | The compounds that improve the stability of the smallpox virus |
KR20240051214A (ko) | 2021-09-03 | 2024-04-19 | 버베리안 노딕 에이/에스 | 변형 백시니아 바이러스 앙카라(mva)에 의한 세포독성 전이유전자 발현의 하향조절을 위한 마이크로rna의 활용 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
WO1989005823A1 (en) | 1987-12-23 | 1989-06-29 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US6730305B1 (en) | 2000-05-08 | 2004-05-04 | The Uab Research Foundation | Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
JPH05509231A (ja) | 1990-07-24 | 1993-12-22 | ザ ユーエイビー リサーチ ファンデーション | ウシrsウイルスの組換えdna、タンパク質ワクチン、抗体、および形質転換細胞の使用法 |
GB9200117D0 (en) | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
DE69509103T2 (de) | 1994-08-25 | 1999-09-30 | Pepscan Systems Bv | Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv-infektionen |
FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6083925A (en) | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US6180398B1 (en) | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
US6699478B1 (en) | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
FR2798857B1 (fr) * | 1999-09-23 | 2003-06-06 | Pf Medicament | Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale |
US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
SG106639A1 (en) | 2000-10-10 | 2004-10-29 | Gen Electric | Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating |
ATE412666T1 (de) | 2000-10-18 | 2008-11-15 | Us Gov Health & Human Serv | Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
CN101831411A (zh) | 2002-05-16 | 2010-09-15 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
EP1768993A4 (en) | 2004-06-16 | 2008-07-23 | Univ Johns Hopkins | CYSTEINE-RICH REGION OF SYNCYTIAL RESPIRATORY VIRUS AND METHODS OF USE THEREOF |
US20080193478A1 (en) * | 2004-08-27 | 2008-08-14 | Rajesh Jain | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus |
WO2008115199A2 (en) * | 2006-08-18 | 2008-09-25 | The University Of North Carolina At Chapel Hill | Chimeric virus vaccines |
WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
DE102006060799A1 (de) | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
CA2684578A1 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
KR100938105B1 (ko) * | 2007-09-21 | 2010-01-21 | 이화여자대학교 산학협력단 | 호흡기 신시치아 바이러스 백신 |
EA021393B1 (ru) | 2007-12-24 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Рекомбинантные антигены rsv |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
CA2743012A1 (en) | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Rsv f vlps and methods of manufacture and use thereof |
CA2742247C (en) | 2008-11-21 | 2017-07-04 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
LT3067064T (lt) * | 2008-12-09 | 2020-09-10 | Novavax, Inc. | Modifikuoti rsv f baltymai ir jų panaudojimo būdai |
WO2010075491A2 (en) | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
JP5796011B2 (ja) | 2009-06-24 | 2015-10-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
SI2445526T1 (sl) | 2009-06-24 | 2016-08-31 | Glaxosmithkline Biologicals S.A. | Rekombinantni RSV antigeni |
ES2918381T3 (es) * | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
EP2461825B1 (en) * | 2009-08-04 | 2017-05-31 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Anti-rsv immunogens and methods of immunization |
KR20120081587A (ko) | 2009-09-10 | 2012-07-19 | 노파르티스 아게 | 기도 질병에 대한 조합 백신 |
WO2011046925A1 (en) | 2009-10-12 | 2011-04-21 | Technovax, Inc. | Respiratory syncytial virus (rsv) virus-like particles (vlps) |
CA2777808C (en) | 2009-11-12 | 2015-01-13 | Trojan Technologies | Cleaning apparatus, radiation source module and fluid treatment system |
AU2011209175B2 (en) | 2010-01-28 | 2016-02-04 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
WO2012006395A1 (en) * | 2010-07-07 | 2012-01-12 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
JP5986580B2 (ja) * | 2010-12-17 | 2016-09-06 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | デザイン要素を含む相互作用する表面要素を有する容器 |
WO2012085936A2 (en) * | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
-
2013
- 2013-03-15 CA CA2879915A patent/CA2879915C/en active Active
- 2013-03-15 KR KR1020157005085A patent/KR102264852B1/ko active IP Right Grant
- 2013-03-15 KR KR1020227028479A patent/KR20220119527A/ko not_active Application Discontinuation
- 2013-03-15 KR KR1020217017594A patent/KR102435054B1/ko active IP Right Grant
- 2013-03-15 CN CN201811121036.XA patent/CN109266622B/zh active Active
- 2013-03-15 JP JP2015524681A patent/JP6523955B2/ja active Active
- 2013-03-15 EP EP13717721.8A patent/EP2879702B9/en active Active
- 2013-03-15 WO PCT/EP2013/055483 patent/WO2014019718A1/en active Application Filing
- 2013-03-15 EA EA201590304A patent/EA031453B1/ru not_active IP Right Cessation
- 2013-03-15 IN IN1448DEN2015 patent/IN2015DN01448A/en unknown
- 2013-03-15 AU AU2013298915A patent/AU2013298915B2/en active Active
- 2013-03-15 MX MX2015001479A patent/MX362511B/es active IP Right Grant
- 2013-03-15 CA CA3158572A patent/CA3158572A1/en active Pending
- 2013-03-15 EA EA201891945A patent/EA201891945A3/ru unknown
- 2013-03-15 CN CN201380040909.3A patent/CN104540520B/zh active Active
- 2013-03-15 SG SG11201500696VA patent/SG11201500696VA/en unknown
- 2013-03-15 SI SI201331652T patent/SI2879702T1/sl unknown
- 2013-03-15 MY MYPI2015700265A patent/MY171498A/en unknown
- 2013-03-15 US US14/417,779 patent/US9480738B2/en active Active
- 2013-03-15 NZ NZ704005A patent/NZ704005A/en unknown
- 2013-03-15 EP EP19211547.5A patent/EP3656396A1/en not_active Withdrawn
- 2013-03-15 BR BR112015002131-0A patent/BR112015002131B1/pt active IP Right Grant
-
2015
- 2015-01-15 IL IL236744A patent/IL236744B/en unknown
- 2015-01-30 MX MX2023003746A patent/MX2023003746A/es unknown
- 2015-01-30 MX MX2019000933A patent/MX2019000933A/es unknown
- 2015-06-25 HK HK15106038.4A patent/HK1205459A1/xx unknown
-
2016
- 2016-10-14 US US15/294,480 patent/US9717787B2/en active Active
-
2017
- 2017-07-28 US US15/662,382 patent/US10124058B2/en active Active
-
2018
- 2018-11-09 US US16/185,125 patent/US10532094B2/en active Active
-
2020
- 2020-01-09 US US16/737,969 patent/US10946089B2/en active Active
- 2020-01-21 CY CY20201100050T patent/CY1122717T1/el unknown
-
2021
- 2021-03-15 US US17/202,230 patent/US20210196814A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116634A patent/JP2023139095A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000933A (es) | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). | |
WO2016109792A8 (en) | Novel multivalent nanoparticle-based vaccines | |
WO2016034678A3 (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
NZ630649A (en) | Vaccine against rsv | |
MX350274B (es) | Vacunas para hsv-2. | |
ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
MX360415B (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
CO6700818A2 (es) | Vectores de parapoxvirus | |
AU2013352179A8 (en) | Computationally optimized broadly reactive antigens for H1N1 influenza | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
EA201992602A3 (ru) | Вакцины против впг-2 | |
WO2012064816A3 (en) | Methods of neutralizing viral infection |